ImmunityBio, Inc. (IBRX) Covered Calls
ImmunityBio, Inc. is a commercial-stage biotechnology company developing next-generation immunotherapies for cancer and infectious diseases. The company utilizes its proprietary IL-15 superagonist platform to activate innate and adaptive immune systems. Its lead product, ANKTIVA, is designed to enhance natural killer and T-cell activity to provide durable, chemotherapy-free treatment options for various solid tumors and hematologic malignancies.
You can sell covered calls on ImmunityBio, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for IBRX (prices last updated Mon 4:16 PM ET):
| ImmunityBio, Inc. (IBRX) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 8.45 | -0.22 | 8.46 | 8.48 | 25.4M | - | 8.9 |
| Covered Calls For ImmunityBio, Inc. (IBRX) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 8.5 | 0.40 | 8.08 | 5.0% | 152% | |
| Apr 17 | 9 | 1.00 | 7.48 | 13.4% | 122% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
ImmunityBio, Inc. (IBRX) is a biotechnology innovator focused on orchestrating the immune system to combat life-threatening diseases. The company’s core strategy involves leveraging its interleukin-15 (IL-15) superagonist platform to activate Natural Killer (NK) cells and T cells, creating a sustained immune response against cancerous cells.
Core Business and Products
- ANKTIVA (N-803): The flagship product, which has received regulatory approval for non-muscle invasive bladder cancer (NMIBC). It is also being studied for its effectiveness in non-small cell lung cancer and other solid tumors.
- Cell Therapy Platforms: The company utilizes off-the-shelf natural killer cells (t-haNK) and chimeric antigen receptor (CAR) technologies to target specific cancer markers without the need for traditional chemotherapy.
- Adenovirus Vaccine Vectors: Proprietary hAd5 technology is used to deliver tumor-associated antigens, stimulating a robust cellular immune response.
Competitive Landscape
ImmunityBio operates in the highly competitive immuno-oncology sector. It competes with major pharmaceutical firms that produce checkpoint inhibitors and other biologics. Key competitors with publicly traded options include Merck, whose blockbuster drug Keytruda is a standard in cancer care, and Bristol-Myers Squibb, which develops Opdivo. Other notable peers in the biotechnology space include BioNTech and Gilead, both of which are heavily invested in advanced cell therapies and oncology platforms.
Strategic Outlook and Innovation
The company is focused on the global commercial scale-up of its approved therapies and expanding its clinical pipeline. By pursuing chemotherapy-free treatment regimens, ImmunityBio seeks to redefine the standard of care for patients who have failed prior therapies. Ongoing research explores the synergy between IL-15 superagonists and checkpoint inhibitors to overcome tumor resistance and improve long-term survival rates.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | KSS covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | OWL covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | USO covered calls | |
Want more examples? IBP Covered Calls | IBUY Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
